BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 17277961)

  • 1. [Introduction to bisphosphonates. History and functional mechanisms].
    Fleisch H
    Orthopade; 2007 Feb; 36(2):103-4, 106-9. PubMed ID: 17277961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates: the first 40 years.
    Russell RG
    Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of action of the bisphosphonates.
    Fleisch H
    Medicina (B Aires); 1997; 57 Suppl 1():65-75. PubMed ID: 9567358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonate therapeutics in bone disease: the hard and soft data on osteoclast inhibition.
    Drake MT; Cremers SC
    Mol Interv; 2010 Jun; 10(3):141-52. PubMed ID: 20539033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Independent pathways in the modulation of osteoclastic resorption by intermediates of the mevalonate biosynthetic pathway: the role of the retinoic acid receptor.
    van Beek E; Löwik C; Karperien M; Papapoulos S
    Bone; 2006 Feb; 38(2):167-71. PubMed ID: 16165408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonates: The role of chemistry in understanding their biological actions and structure-activity relationships, and new directions for their therapeutic use.
    Ebetino FH; Sun S; Cherian P; Roshandel S; Neighbors JD; Hu E; Dunford JE; Sedghizadeh PP; McKenna CE; Srinivasan V; Boeckman RK; Russell RGG
    Bone; 2022 Mar; 156():116289. PubMed ID: 34896359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates: mode of action and pharmacology.
    Russell RG
    Pediatrics; 2007 Mar; 119 Suppl 2():S150-62. PubMed ID: 17332236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of bisphosphonates.
    Fleisch H
    Breast Cancer Res; 2002; 4(1):30-4. PubMed ID: 11879557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
    Dunford JE; Thompson K; Coxon FP; Luckman SP; Hahn FM; Poulter CD; Ebetino FH; Rogers MJ
    J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diphosphonates: history and mechanisms of action.
    Fleisch H
    Metab Bone Dis Relat Res; 1981; 3(4-5):279-87. PubMed ID: 6300612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonates: from bench to bedside.
    Russell RG
    Ann N Y Acad Sci; 2006 Apr; 1068():367-401. PubMed ID: 16831938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between the chemistry and biological activity of the bisphosphonates.
    Ebetino FH; Hogan AM; Sun S; Tsoumpra MK; Duan X; Triffitt JT; Kwaasi AA; Dunford JE; Barnett BL; Oppermann U; Lundy MW; Boyde A; Kashemirov BA; McKenna CE; Russell RG
    Bone; 2011 Jul; 49(1):20-33. PubMed ID: 21497677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The chemistry of bisphosphonates: from antiscaling agents to clinical therapeutics.
    Widler L; Jahnke W; Green JR
    Anticancer Agents Med Chem; 2012 Feb; 12(2):95-101. PubMed ID: 21864230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates.
    van beek E; Löwik C; van der Pluijm G; Papapoulos S
    J Bone Miner Res; 1999 May; 14(5):722-9. PubMed ID: 10320520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mevalonates restore zoledronic acid-induced osteoclastogenesis inhibition.
    Nagaoka Y; Kajiya H; Ozeki S; Ikebe T; Okabe K
    J Dent Res; 2015 Apr; 94(4):594-601. PubMed ID: 25535203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonate-osteoclasts: changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients.
    Jobke B; Milovanovic P; Amling M; Busse B
    Bone; 2014 Feb; 59():37-43. PubMed ID: 24211427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
    Coxon FP; Helfrich MH; Van't Hof R; Sebti S; Ralston SH; Hamilton A; Rogers MJ
    J Bone Miner Res; 2000 Aug; 15(8):1467-76. PubMed ID: 10934645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Inhibitory effects of bisphosphonates on bone resorption].
    Shinoda H
    Nihon Yakurigaku Zasshi; 1995 May; 105(5):285-94. PubMed ID: 7628780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.
    Russell RG; Watts NB; Ebetino FH; Rogers MJ
    Osteoporos Int; 2008 Jun; 19(6):733-59. PubMed ID: 18214569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New therapy using bisphosphonate for urolithiasis].
    Yasui T; Niimi K; Hirose M
    Clin Calcium; 2011 Oct; 21(10):1511-5. PubMed ID: 21960237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.